Barclays Reaffirms Their Hold Rating on Exelixis (EXEL)
William Blair Maintains Exelixis(EXEL.US) With Buy Rating
Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), ImmunityBio (IBRX) and Exelixis (EXEL)
JMP Securities Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $41
Guggenheim Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $42
Exelixis (EXEL) Gets a Buy From RBC Capital
Guggenheim Remains a Buy on Exelixis (EXEL)
Truist Financial Maintains Exelixis(EXEL.US) With Buy Rating
Exelixis Price Target Maintained With a $40.00/Share by HC Wainwright & Co.
Exelixis Analyst Ratings
Citi Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $45
JMP Securities Maintains Exelixis(EXEL.US) With Buy Rating, Maintains Target Price $41
Exelixis Gains Buy Rating From Silvan Tuerkcan Following Early FDA Approval and Growth Potential in Neuroendocrine Tumor Market
BofA Securities Maintains Exelixis(EXEL.US) With Hold Rating, Maintains Target Price $39
RBC Capital Maintains Exelixis(EXEL.US) With Buy Rating, Raises Target Price to $40
Truist Financial Maintains Exelixis(EXEL.US) With Buy Rating
Exelixis Is Maintained at Outperform by RBC Capital
Exelixis Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Werewolf Therapeutics (HOWL), Exelixis (EXEL)
Exelixis Analyst Ratings